Table 1.
Baseline patient characteristics
| Total | CMT | ABVD only | |
|---|---|---|---|
| No. patients (%) | 127 | 61 (48.0) | 66 (52.0) |
| Median age, (range) (years) | 42 (18–78) | 34 (19–76) | 48 (18–78) |
| Sex, n (%) | |||
| Male | 75 (59.1) | 31 (24.4) | 44 (34.7) |
| Female | 52 (40.9) | 30 (23.6) | 22 (17.3) |
| Histology, n (%) | |||
| Nodular sclerosis | 55 (43.3) | 28 (22.0) | 27 (21.3) |
| Lymphocyte rich | 20 (15.7) | 8 (6.2) | 12 (9.5) |
| Lymphocyte depleted | 11 (8.7) | 6 (4.8) | 5 (3.9) |
| Mixed cellularity | 41 (32.3) | 19 (15.0) | 22 (17.3) |
| Stage, n (%) | |||
| I | 27 (21.3) | 13 (10.3) | 14 (11.0) |
| II | 100 (78.7) | 48 (37.8) | 52 (40.9) |
| ECOG PS ≥2 | 11 (8.7) | 5 (3.9) | 6 (4.8) |
| B symptoms, n (%) | 24 (18.9) | 11 (8.7) | 13 (10.3) |
| ESR, n (%) | |||
| ≥50 mm/L | 31 (24.4) | 13 (10.3) | 18 (14.1) |
| No. involved sites (%) | |||
| 1–2 | 49 (38.6) | 25 (19.7) | 24 (18.9) |
| ≥3 | 78 (61.4) | 36 (28.3) | 42 (33.1) |
| EN site involvement, n (%) | 30 (23.6) | 15 (11.8) | 15 (11.8) |
| Mediastinum | 19 (14.9) | 9 (7.0) | 10 (7.9) |
| Other | 11 (8.7) | 6 (4.8) | 5 (3.9) |
| Bulky disease, n (%) | 27 (21.3) | 16 (12.6) | 11 (8.7) |
ABVD, doxorubicin, bleomycin, vinblastine, dacarbazine; CMT, combined modality treatment; ECOG, Eastern Cooperative Oncology Group; EN, extra‐nodal site; ESR, erythrocyte sedimentation rate; PS, performance status.